Skip to main
BEAT

HeartBeam (BEAT) Stock Forecast & Price Target

HeartBeam (BEAT) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

HeartBeam Inc. is well-positioned for growth as it seeks FDA clearance for its innovative telehealth products based on its patented Vector Electrocardiography (VECG) technology, which demonstrates strong equivalence to existing 12-lead systems. The company's strategic focus on capturing both premium direct-pay customers and large-scale reimbursement channels could unlock an annual revenue potential of $1.3 to $2.6 billion, supported by a projected increase in the global mobile ECG device market from $4.1 billion in 2024 to $8.9 billion by 2032. Additionally, the rising mobile healthcare devices market, estimated to grow from $155 billion in 2025 to $745.7 billion by 2035, reinforces the demand for early and remote cardiac diagnostics, suggesting strong long-term economic prospects for HeartBeam's offerings.

Bears say

HeartBeam Inc. faces significant financial risks due to the potential for inadequate or delayed reimbursement for its products, which could materially impact demand and result in negative revenue and operating results. The company's performance metrics show reduced effectiveness in "spot" mode for its ECG systems, raising concerns about the reliability of its technology in critical situations. Furthermore, the auditors’ going-concern opinion, coupled with forecasts of continued negative cash flows and potential dilution of stockholder value through new funding, underscores the substantial challenges HeartBeam could face in sustaining operations without additional capital.

HeartBeam (BEAT) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of HeartBeam and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About HeartBeam (BEAT) Forecast

Analysts have given HeartBeam (BEAT) a Strong Buy based on their latest research and market trends.

According to 2 analysts, HeartBeam (BEAT) has a Strong Buy consensus rating as of Jan 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

HeartBeam (BEAT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.